Knight Therapeutics Inc T.GUD

New Press Release - Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

Achieved Record Annual Revenues and EBITDA MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended...read article.

[luscar99]

This post has been removed in accordance with Community Policy

[wofats]

You said everything is bad  This? Revenues were $328,199, an increase of $34,636 or 12% over prior year. Revenues excluding IAS 29 were $343,138, an increase of $51,368 or 18% over prior year. Gross margin was $152,652 or 47% compared to $138,061 or 47% in prior year. Adjusted EBITDA1 was $60,075, an increase of $6,043 or 11% over prior year. Adjusted EBITDA per

[luscar99]

This post has been removed in accordance with Community Policy

[longrun86]

Q4 was gross and the 2024 Guidance was underwhelming. The impairment bothers me a bit but I also understand that currency issue. I haven't listened to the conference call recording but will this weekend. Overall I am dissapointed but will hang tight for now. LR